What's Happening?
Genentech, a member of the Roche Group, has announced positive results from its Phase II ZUPREME-1 trial for petrelintide, an investigational drug aimed at treating overweight and obesity. The trial involved 493 participants with a mean BMI of 37 kg/m²
and demonstrated that once-weekly subcutaneous injections of petrelintide resulted in statistically significant weight loss compared to a placebo. Participants achieved up to a 10.7% mean weight loss from baseline after 42 weeks, compared to 1.7% with placebo. The trial also highlighted petrelintide's favorable tolerability profile, with no unexpected safety signals and a low rate of treatment discontinuation due to adverse events. The study's results support further development of petrelintide for chronic weight management.
Why It's Important?
The development of petrelintide is significant as obesity is a major risk factor for chronic diseases globally, affecting healthcare systems due to associated comorbidities. With over half of the global population projected to be living with overweight and obesity by 2035, effective treatments are crucial. Petrelintide's promising results could provide a new option for weight management, addressing unmet medical needs. The drug's ability to achieve meaningful weight loss with a well-tolerated dosing approach could support long-term benefits for individuals struggling with obesity, potentially reducing the burden on healthcare systems and improving quality of life.
What's Next?
Genentech plans to present the final ZUPREME-1 data at an upcoming medical congress, which will inform the design of Phase III trials. Additionally, results from a second Phase II trial, ZUPREME-2, evaluating petrelintide in people with obesity or overweight and type 2 diabetes, are expected in the second half of 2026. A Phase II trial exploring the combination of petrelintide with another drug, CT-388, is also planned for later in 2026. These steps indicate Genentech's commitment to advancing its cardiometabolic portfolio and addressing the diverse needs of people living with obesity.
